DR. ROBERT ISRAEL, M.D.
Osteopathic Medicine at Oxford Dr, Airmont, NY
License number
New York 156732
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
50 Oxford Dr, Airmont, NY 10901
Phone
(914) 789-2827
(845) 368-8120 (Fax)
(845) 368-8120 (Fax)
Personal information
See more information about ROBERT ISRAEL at radaris.comName
Address
Phone
471 Lake Desolation Rd, Middle Grove, NY 12850
50 Oxford Dr, Suffern, NY 10901
345 E 73Rd St APT 4H, New York, NY 10021
333 E 34Th St APT 2A, New York, NY 10016
335 State St, Brooklyn, NY 11217
Organization information
See more information about ROBERT ISRAEL at bizstanding.comRobert Israel MD
50 Oxford Dr, Suffern, NY 10901
Industry:
Internist
Phone:
(914) 789-2827 (Phone)
Robert Joseph Israel
Professional information
Dr. Robert Israel, Suffern NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
50 Oxford Dr, Suffern 10901
(914) 789-2827 (Phone), (845) 368-8120 (Fax)
(914) 789-2827 (Phone), (845) 368-8120 (Fax)
Certifications:
Internal Medicine, 1985, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1982
North Shore University Hospital
Memorial Sloan-Kettering Cancer Center
Perelman School of Medicine University of Pennsylvania
Graduated: 1982
North Shore University Hospital
Memorial Sloan-Kettering Cancer Center
Methods For Reducing Viral Load In Hiv-1-Infected Patients
US Patent:
2008024, Oct 2, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894762
Inventors:
William C. Olson - Ossining NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/395, A61P 43/00
US Classification:
4241331
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
Cd4-Igg2-Based Salvage Therapy Of Hiv-1 Infection
US Patent:
2003021, Nov 13, 2003
Filed:
Mar 12, 2003
Appl. No.:
10/386763
Inventors:
William Olson - Ossining NY, US
Robert Israel - Suffern NY, US
Robert Israel - Suffern NY, US
International Classification:
A61K039/42, C12Q001/70
US Classification:
435/005000, 424/144100, 424/160100
Abstract:
This invention provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). Finally, this invention provides a method of inhibiting HIV infection of a CD4+ cell, a method of preventing a subject from being infected with HIV, and a method of treating a subject infected with HIV so as to block the spread of HIV infection, using the above CD-4-IgG2 chimeric heterotetramers.
Methods For Reducing Viral Load In Hiv-1 Infected Patients
US Patent:
2011020, Aug 18, 2011
Filed:
Nov 24, 2010
Appl. No.:
12/954464
Inventors:
WILLIAM C. OLSON - OSSINING NY, US
PAUL J. MADDON - SCARSDALE NY, US
DANIEL C. PEVEAR - MEDFORD MA, US
ROBERT J. ISRAEL - SUFFERN NY, US
JOSE D. MURGA - ROSEDALE NY, US
PAUL J. MADDON - SCARSDALE NY, US
DANIEL C. PEVEAR - MEDFORD MA, US
ROBERT J. ISRAEL - SUFFERN NY, US
JOSE D. MURGA - ROSEDALE NY, US
International Classification:
A61K 39/395, A61P 31/18
US Classification:
4241331, 4241431
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
Methods For Reducing Viral Load In Hiv-1-Infected Patients
US Patent:
2007002, Feb 1, 2007
Filed:
Jul 21, 2006
Appl. No.:
11/491330
Inventors:
William Olson - Ossining NY, US
Paul Maddon - Scarsdale NY, US
Daniel Pevear - Medford MA, US
Robert Israel - Suffern NY, US
Jose Murga - Rosedale NY, US
Paul Maddon - Scarsdale NY, US
Daniel Pevear - Medford MA, US
Robert Israel - Suffern NY, US
Jose Murga - Rosedale NY, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435006000, 435007100
Abstract:
This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5CD4 target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
Methods For Killing Psma-Expressing, Taxane-Resistant Cancer Cells
US Patent:
2011025, Oct 13, 2011
Filed:
Feb 17, 2011
Appl. No.:
13/030105
Inventors:
Dangshe Ma - Millwood NY, US
William C. Olson - Yorktown Heights NY, US
Stephen Morris - Croton on Hudson NY, US
Robert J. Israel - Suffern NY, US
William C. Olson - Yorktown Heights NY, US
Stephen Morris - Croton on Hudson NY, US
Robert J. Israel - Suffern NY, US
Assignee:
PSMA Development Company, LLC - Tarrytown NY
International Classification:
A61K 39/395, A61P 35/00, A61P 35/04, C07K 16/30
US Classification:
4241811, 4241781, 5303917
Abstract:
Methods of killing prostate-specific membrane antigen (PSMA)-expressing, taxane-resistant cancer cells are provided. In particular, PSMA-expressing, taxane-resistant cancer cells are contacted with an antibody-drug conjugate (ADC) that comprises an antibody or antigen-binding fragment thereof that specifically binds to PSMA conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine.
Methods For Reducing Viral Load In Hiv-1 Infected Patients
US Patent:
2013021, Aug 22, 2013
Filed:
Sep 17, 2012
Appl. No.:
13/621590
Inventors:
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
Daniel C. Pevear - Medford MA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
Assignee:
Progenics Pharmaceuticals, Inc. - Tarrytown NY
International Classification:
A61K 39/395
US Classification:
4241331, 5303873, 5303896, 4241731
Abstract:
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist.
Methods For Reducing Viral Load In Hiv-1 Infected Patients
US Patent:
2010017, Jul 15, 2010
Filed:
Oct 30, 2009
Appl. No.:
12/590005
Inventors:
William C. Olson - Yorktown Heights NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Downingtown PA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
Paul J. Maddon - Scarsdale NY, US
Daniel C. Pevear - Downingtown PA, US
Robert J. Israel - Suffern NY, US
Jose D. Murga - Rosedale NY, US
International Classification:
A61K 39/395, C07K 16/18
US Classification:
4241331, 4241441, 4241781, 5303881, 5303911
Abstract:
This invention provides a method of reducing viral load in an HIV-1-infected human subject which comprises administering to the subject an effective HIV-1 viral load reducing dose of a CCR5 receptor antagonist, such as a humanized antibody designated PRO 140 or an anti-CCR5 receptor monoclonal antibody, wherein the viral load reducing dose achieves an average maximum decrease of viral load in the subject of at least 1.83 logto 2.5 logat about ten days following administration of the CCR5 receptor antagonist and wherein the viral load reducing dose further achieves a mean viral load reduction of 1.7 logat about nine days following administration of the CCR5 receptor antagonist.
Use Of Methylnaltrexone To Treat Irritable Bowel Syndrome
US Patent:
2005000, Jan 6, 2005
Filed:
Apr 8, 2004
Appl. No.:
10/821813
Inventors:
Thomas Boyd - Grandview NY, US
Robert Israel - Suffern NY, US
Suketu Sanghvi - Kendall Park NJ, US
Robert Israel - Suffern NY, US
Suketu Sanghvi - Kendall Park NJ, US
International Classification:
A61K031/485
US Classification:
514282000, 514279000
Abstract:
Methods of treating irritable bowel syndrome with peripheral opioid antagonists, such as methylnaltrexone, are provided. Formulations comprising peripheral opioid antagonists, such as methylnaltrexone, and irritable bowel syndrome therapeutic agents are also provided.
Use Of Methylnaltrexone And Related Compounds To Treat Post-Operative Gastrointestinal Dysfunction
US Patent:
2006020, Sep 14, 2006
Filed:
Jan 20, 2006
Appl. No.:
11/336418
Inventors:
Robert Israel - Suffern NY, US
International Classification:
A61K 31/485
US Classification:
514282000
Abstract:
Methods and compositions for treating post-surgical gastrointestinal dysfunction are provided. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a patient after a segmental colectomy is performed on the patient.